KLRG1 blockade works synergistically with PD-1 checkpoint therapy, which increases the frequency and maturation of CD8+ T-cells and NK cells in the tumor microenvironment, promoting antitumor immunity against melanoma tumor growth [23]. The gene discussed is PDCD1; the disease is neoplasm.